CLINICAL EVENTS CALENDAR
Non-Accredited Education
 CLINICAL EXPERIENCE WITH A NEW HYBRID CORONARY WIRE On Demand Web ArchiveNon-Accredited Target Audience: Physicians, nurses, and technologists. This activity is supported by an educational grant from Terumo Medical Corporation. |
French Physicians to Conduct 2000-Patient Study of CATANIA™ Coronary Stent
NEWNAN, Ga., Oct. 30 /PRNewswire/ -- Physicians at more than 40 centers in France have joined a study of the CATANIA™ Coronary Stent with NanoThin Polyzene®-F manufactured by CeloNova BioSciences. With Professor Emmanuel Teiger and Doctor Paul Barragan as co-Principal Investigators, the researchers today announced the Assessment of The Latest Non-Thrombogenic Angioplasty (ATLANTA-France) stent study. Each center will enroll 50 patients with the first procedures expected in early November."
The study will evaluate the short-, mid- and long-term safety and efficacy of the CATANIA™ coronary stent for the treatment of up to three de novo native coronary artery lesions in a real world setting. "Professor Teiger and Doctor Barragan are independent and respected interventional cardiologists and we look forward to the results of their study," said Thomas A. Gordy, President and Chief Executive Officer of CeloNova BioSciences. "Physicians throughout France have already used the CATANIA™ stent, but this registry will increase participation over a broad spectrum of new facilities and give patients access to a stent without drugs on the surface and for which they do not have to take long-term dual antiplatelet therapy."
The CATANIA™ stent is CE Marked and available throughout the European Union, in the Middle East, and Northern Africa. The stent, treated with CeloNova's anti-thrombotic and bacterial resistant Polyzene®-F surface is available in 60 sizes.
About CeloNova BioSciences, Inc.
About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova develops novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment. The Company's current products include Embozene™ Color-Advanced Microspheres and the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F. Both products are CE Marked. Embozene™ Microspheres have been approved by the FDA for the treatment of hypervascular tumors and arteriovenous malformations. For more information, please visit www.celonova.com.
Cardiology Blogs
All Subscriptions are FREE to qualified cardiology professionals
- Subscribe to:
- Journal
- Digital Journal
- E-News
- RSS feed
Anytown, California
Press Release
— Bethlehem, Pennsylvania – Invatec received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October to market its Mo.Ma Ultra Proximal Cerebral Protection Device for use during carotid artery stenting (CAS). The device effectively reduces and captures debris released during the stenting procedure to prevent it from traveling to the brain, where it has the potential to cause a stroke.
CME Showcase
 The Use of Remote Robotic Navigation in Complex Arrhythmias Complimentary Accredited Web Archive This activity is designed for electrophysiologists and EP allied professionals. Diagnosing Coronary Artery Disease: Advanced Cardiovascular Imaging Solutions  New Standards of Care for CRMD Antibiotic Protection Complimentary CME Accredited Webcast Dates: November 18, 2008 Time: 6:00 pm ET November 19, 2008 Time: 3:00 pm ET This activity is sponsored by the North American Center for Continuing Medical Education. |
REVIEW OUR OTHER
CARDIOLOGY BRANDS Check out our other resources for healthcare professionals of all specialties.
